{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:56:32Z","timestamp":1792173392572,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":3172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1111\/jth.12485","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T09:55:56Z","timestamp":1386928556000},"page":"320-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":455,"title":["Effectiveness and safety of novel oral anticoagulants as compared with vitamin\u00a0K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta\u2010analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"T.","family":"van der Hulle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kooiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"den Exter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12485_bb0010","first-page":"CD001367","article-title":"Duration of treatment with vitamin\u00a0K antagonists in symptomatic venous thromboembolism","author":"Hutten","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.12485_bb0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case\u2010fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.12485_bb0020","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta\u2010analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.12485_bb0025","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3\u00a0months of anticoagulant therapy","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.12485_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH09-05-0327","article-title":"New oral anticoagulant drugs in cardiovascular disease","volume":"104","author":"Ahrens","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0035","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0040","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0045","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0055","first-page":"799","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jth.12124","article-title":"Diagnostic management of acute deep vein thrombosis and pulmonary embolism","volume":"11","author":"Huisman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose\u2010guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE\u00a0I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0070","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0075","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep vein thrombosis with the oral direct factor\u00a0Xa inhibitor rivaroxaban (BAY 59\u20107939): the ODIXa\u2010DVT (Oral Direct Factor\u00a0Xa Inhibitor BAY 59\u20107939 in Patients With Acute Symptomatic Deep Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jth.12485_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor\u00a0Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose\u2010ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0049-3848(02)00259-1","article-title":"Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis","volume":"107","author":"Wahlander","year":"2002","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12485_bb0095","first-page":"205","article-title":"A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE\u2010COVER\u00a0II)","volume":"118","author":"Schulman","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/jth.12485_bb0100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low\u2010molecular\u2010weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/jth.12485_bb0105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12485_bb0120","doi-asserted-by":"crossref","first-page":"e7498","DOI":"10.1136\/bmj.e7498","article-title":"Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta\u2010analysis of randomised controlled trials","volume":"345","author":"Fox","year":"2012","journal-title":"BMJ"},{"key":"10.1111\/jth.12485_bb0125","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta\u2010analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"key":"10.1111\/jth.12485_bb0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","article-title":"Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?","volume":"35","author":"Dale","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12485_bb0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0609.2009.01230.x","article-title":"Rivaroxaban \u2013 an oral, direct factor\u00a0Xa inhibitor: lessons from a broad clinical study programme","volume":"82","author":"Haas","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12485_bb0140","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo\u2010controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12485_bb0145","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/CIRCULATIONAHA.112.123224","article-title":"Periprocedural management and approach to bleeding in patients taking dabigatran","volume":"126","author":"Weitz","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jth.12485_bb0150","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jth.12485_bb0155","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jth.12294","article-title":"Impact of double\u2010blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta\u2010analysis","volume":"11","author":"Lega","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12485_bb0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1160\/TH12-10-0715","article-title":"Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double\u2010blind conditions?","volume":"109","author":"O'Neil","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12485","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622038727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622038727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12485\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:06:42Z","timestamp":1761534402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622038727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1538783622038727"],"URL":"https:\/\/doi.org\/10.1111\/jth.12485","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718207436.793499773","asserted-by":"object"}]},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin\u00a0K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta\u2010analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}